CL2008002868A1 - Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica. - Google Patents

Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica.

Info

Publication number
CL2008002868A1
CL2008002868A1 CL2008002868A CL2008002868A CL2008002868A1 CL 2008002868 A1 CL2008002868 A1 CL 2008002868A1 CL 2008002868 A CL2008002868 A CL 2008002868A CL 2008002868 A CL2008002868 A CL 2008002868A CL 2008002868 A1 CL2008002868 A1 CL 2008002868A1
Authority
CL
Chile
Prior art keywords
reboxetine
fibromyalgia
migraine
headache
racemic
Prior art date
Application number
CL2008002868A
Other languages
English (en)
Spanish (es)
Inventor
Clyde Marshall Robert
Ahmed Saeeduddlin
Mcarthur Robert
P Taylor Duncan
Birgenson Lars
H F Wong Erik
C Pasquale
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002868(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of CL2008002868A1 publication Critical patent/CL2008002868A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2008002868A 1999-07-01 2008-09-26 Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica. CL2008002868A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14196899P 1999-07-01 1999-07-01
US14413199P 1999-07-16 1999-07-16
US15825699P 1999-10-06 1999-10-06
US17038199P 1999-12-13 1999-12-13

Publications (1)

Publication Number Publication Date
CL2008002868A1 true CL2008002868A1 (es) 2009-01-09

Family

ID=27495506

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2008002868A CL2008002868A1 (es) 1999-07-01 2008-09-26 Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica.
CL2008002867A CL2008002867A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00).
CL2008002866A CL2008002866A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno adictivo, trastorno mental, trastorno de deficit atencional, trastorno bipolar, obesidad, trastorno de panico, trastorno psicotico, sindrome de inhibicion selectiva de la recaptacion de serotonina, entre otras (sol. div. 1765-00).

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2008002867A CL2008002867A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno de ajuste o adaptacion, anorexia nerviosa, bulimia nerviosa, trastorno sistemico, trastorno de intoxicacion, trastorno compulsivos obsesivos, trastorno de desarrollo especifico, trastorno tic, entre otras (sol. div. 1765-00).
CL2008002866A CL2008002866A1 (es) 1999-07-01 2008-09-26 Uso de (s,s)-reboxetina en la preparacion de un medicamento util en el tratamiento de un trastorno adictivo, trastorno mental, trastorno de deficit atencional, trastorno bipolar, obesidad, trastorno de panico, trastorno psicotico, sindrome de inhibicion selectiva de la recaptacion de serotonina, entre otras (sol. div. 1765-00).

Country Status (30)

Country Link
US (18) US6465458B1 (https=)
EP (3) EP2087892A3 (https=)
JP (3) JP2003503450A (https=)
KR (5) KR100935277B1 (https=)
CN (5) CN1660110A (https=)
AR (1) AR035158A1 (https=)
AT (9) ATE305306T1 (https=)
AU (2) AU771258B2 (https=)
BR (1) BR0012136A (https=)
CA (2) CA2643231A1 (https=)
CL (3) CL2008002868A1 (https=)
CO (1) CO5190662A1 (https=)
CZ (1) CZ299847B6 (https=)
DE (9) DE60035232T2 (https=)
DK (4) DK1459749T3 (https=)
EA (6) EA011094B1 (https=)
ES (9) ES2239311T3 (https=)
GE (1) GEP20094798B (https=)
HU (1) HUP0201623A3 (https=)
IL (3) IL147246A0 (https=)
MX (1) MXPA02000562A (https=)
MY (1) MY137348A (https=)
NO (4) NO20016406L (https=)
NZ (2) NZ515885A (https=)
PE (1) PE20010684A1 (https=)
PL (1) PL196996B1 (https=)
PT (5) PT1196172E (https=)
SK (5) SK286668B6 (https=)
TW (9) TW200922594A (https=)
WO (1) WO2001001973A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883408B2 (en) 2018-10-15 2024-01-30 Axsome Therapeutics, Inc. Reboxetine to treat narcolepsy
US11957686B2 (en) 2018-06-17 2024-04-16 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US12115165B2 (en) 2018-10-15 2024-10-15 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
CA2475026A1 (en) * 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
MXPA02010410A (es) * 2000-04-21 2003-04-25 Upjohn Co Tratamiento de los sindromes de fibromialgia y de fatiga cronica.
WO2001081343A2 (en) 2000-04-21 2001-11-01 Pharmacia & Upjohn Company Compounds for treating fibromyalgia and chronic fatigue syndrome
AU2002213830A1 (en) * 2000-10-31 2002-05-15 Head Explorer A/S The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
BR0115301A (pt) * 2000-11-15 2004-12-14 Lilly Co Eli Uso de um inibidor seletivo da recaptação de norepinefrina
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
EA009780B1 (ru) * 2001-06-19 2008-04-28 Норберт Мюллер Применение ингибиторов cox-2 для лечения шизофрении, аффективных расстройств или осложнений, связанных с тиком
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
DE60220825T2 (de) * 2001-11-30 2008-03-06 Eli Lilly And Co., Indianapolis Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
BR0213581A (pt) * 2001-12-11 2004-08-24 Lilly Co Eli Uso de um inibidor de recaptação de norepinefrina seletivo
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
EP1513529B1 (en) * 2002-05-30 2011-12-14 NeuroSearch A/S Triple monoamine reuptake inhibitors for the treatment of chronic pain
CN1662511B (zh) * 2002-06-17 2010-06-09 辉瑞意大利公司 瑞波西汀的药物盐
AR040680A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
WO2004017977A2 (en) 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
EP1546123B1 (en) * 2002-08-23 2006-05-31 Eli Lilly And Company Benzyl morpholine derivatives
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
NZ541009A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
MXPA05007381A (es) * 2003-01-13 2006-02-10 Dynogen Pharmaceuticals Inc Metodo para el tratamiento de transtornos funcionales del intestino.
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2004105690A2 (en) * 2003-05-23 2004-12-09 Cypress Bioscience, Inc. Treatment of chronic pain associated with drug or radiation therapy
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
NZ545494A (en) * 2003-09-12 2009-10-30 Pfizer Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
US7402698B2 (en) 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7419980B2 (en) 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7524846B2 (en) 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7531543B2 (en) 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7550485B2 (en) 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US7365076B2 (en) 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
EP1729754B1 (en) * 2003-12-12 2008-07-02 Eli Lilly And Company Selective norepinephrine reuptake inhibitors for the treatment of hot flashes
EP1716126B1 (en) * 2003-12-23 2009-02-25 Eli Lilly And Company Morpholine derivatives as norepinephrine reuptake inhibitors
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
KR100871272B1 (ko) * 2004-04-30 2008-11-28 화이자 인코포레이티드 모폴린 화합물
BRPI0511941A (pt) * 2004-06-09 2008-01-22 Pfizer uso de (s, s)-reboxetina ou reboxetina racêmica
US7244765B2 (en) * 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20090227562A1 (en) * 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
HRP20100682T4 (hr) 2004-08-13 2014-08-01 Boehringer Ingelheim International Gmbh Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
US20080261955A1 (en) * 2004-10-01 2008-10-23 Timothy Dinan Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
ES2383768T3 (es) * 2006-06-28 2012-06-26 Chelsea Therapeutics Inc. Composiciones farmacéuticas que comprenden droxidopa
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CN101657193A (zh) 2007-03-09 2010-02-24 切尔西治疗公司 用于治疗纤维肌痛的屈昔多巴及其药物组合物
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
AU2008245836A1 (en) * 2007-04-30 2008-11-06 Adolor Corporation Compositions of (-)-E-10-OH-NT and methods for their synthesis and use
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20090233959A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20090233957A1 (en) * 2008-02-19 2009-09-17 Adolor Corporation (-)-beloxepin and methods for its synthesis and use
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2010044016A1 (en) * 2008-10-17 2010-04-22 Pfizer Limited Novel uses for esreboxetine and racemic reboxetine
WO2010120910A1 (en) * 2009-04-15 2010-10-21 Theravance, Inc. 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
AU2010273645B2 (en) * 2009-07-13 2014-12-04 Theravance Biopharma R&D Ip, Llc 3-phenoxymethylpyrrolidine compounds
US8273786B2 (en) 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
US8471040B2 (en) 2010-10-11 2013-06-25 Theravance, Inc. Serotonin reuptake inhibitors
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
EP3693020A1 (en) * 2019-02-08 2020-08-12 Burmaster International Group GmbH Potassium enriched topical formulations for pain relief and sleep aid
CA3163505A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4465458A (en) * 1980-03-19 1984-08-14 Matsushita Electric Industrial Co., Ltd. Apparatus for burning liquid fuel equipped with heating-type fuel vaporizer
GB8419683D0 (en) 1984-08-02 1984-09-05 Erba Farmitalia 3-substituted derivatives of 1-amino-2-hydroxy-propane
GB2167407B (en) * 1984-11-22 1988-05-11 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US4596807A (en) 1985-03-26 1986-06-24 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
PH30083A (en) 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
US5281624A (en) 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5192751A (en) 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence
TW344661B (en) 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
IL111786A0 (en) 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
WO1997035584A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
WO1997035586A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
ES2125696T3 (es) 1996-11-27 1999-03-01 Pfleger R Chem Fab Utilizacion del cloruro de tropsio para la produccion de una preparacion farmaceutica para el tratamiento de disfunciones vesicales.
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
WO1998046227A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
AU5155198A (en) 1997-08-28 1999-03-22 Robert Murdock Method and composition for transdermal administration of pharmacologic agent
US5942530A (en) 1997-08-28 1999-08-24 Eli Lilly And Company Method for treating pain
US6622036B1 (en) * 2000-02-09 2003-09-16 Cns Response Method for classifying and treating physiologic brain imbalances using quantitative EEG
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
AU9692898A (en) * 1997-10-17 1999-05-10 Eli Lilly And Company Potentiation of pharmaceuticals
US6586427B2 (en) * 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
IL138855A0 (en) * 1998-04-09 2001-10-31 Upjohn Co New treatments for nervous disorders
IT1305322B1 (it) 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Uso di reboxetina per il trattamento di disturbi nervosi
PT1075264E (pt) * 1998-05-08 2005-01-31 Upjohn Co Novas combinacoes farmacologicas de reboxetina e pindolol
CN1331576A (zh) 1998-06-29 2002-01-16 药品应用协会有限公司 用于缓解疼痛的方法和经皮组合物
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US20050096349A1 (en) * 2003-11-03 2005-05-05 University Of Florida Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957686B2 (en) 2018-06-17 2024-04-16 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11883408B2 (en) 2018-10-15 2024-01-30 Axsome Therapeutics, Inc. Reboxetine to treat narcolepsy
US12115165B2 (en) 2018-10-15 2024-10-15 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12246023B2 (en) 2018-10-15 2025-03-11 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12447155B2 (en) 2018-10-15 2025-10-21 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Also Published As

Publication number Publication date
AR035158A1 (es) 2004-05-05
ES2242175T3 (es) 2005-11-01
KR20060099544A (ko) 2006-09-19
DE60019473T2 (de) 2006-02-23
EA005029B1 (ru) 2004-10-28
CZ299847B6 (cs) 2008-12-10
ES2239311T3 (es) 2005-09-16
EA200501496A1 (ru) 2006-06-30
ATE292971T1 (de) 2005-04-15
NO20016406L (no) 2002-02-19
CN1660109A (zh) 2005-08-31
EA200400589A1 (ru) 2004-12-30
PT1196172E (pt) 2006-05-31
EP2087892A2 (en) 2009-08-12
DE60023043T2 (de) 2006-06-14
US20060264436A1 (en) 2006-11-23
CA2375908C (en) 2006-05-30
CN1660108A (zh) 2005-08-31
ATE305306T1 (de) 2005-10-15
CN1379672A (zh) 2002-11-13
EA008381B1 (ru) 2007-04-27
ES2246485T3 (es) 2006-02-16
DK1459749T3 (da) 2006-01-09
CL2008002867A1 (es) 2009-01-09
US20080096890A1 (en) 2008-04-24
PT1459748E (pt) 2005-08-31
TW200922594A (en) 2009-06-01
TWI298255B (en) 2008-07-01
US20020107249A1 (en) 2002-08-08
US7317011B2 (en) 2008-01-08
ATE305788T1 (de) 2005-10-15
US20060128705A1 (en) 2006-06-15
CN1205935C (zh) 2005-06-15
EA200200111A1 (ru) 2002-06-27
JP2003503450A (ja) 2003-01-28
US20080103146A1 (en) 2008-05-01
IL147246A0 (en) 2002-08-14
AU2004202096B2 (en) 2005-10-20
DE60020613D1 (de) 2005-07-07
EP2087892A3 (en) 2009-09-30
TW200607511A (en) 2006-03-01
NO20091158L (no) 2002-02-19
CN1660110A (zh) 2005-08-31
PT1632234E (pt) 2007-07-09
AU5633700A (en) 2001-01-22
NO20091159L (no) 2002-02-19
KR20090087134A (ko) 2009-08-14
EA006652B1 (ru) 2006-02-24
SK286669B6 (sk) 2009-03-05
ATE319453T1 (de) 2006-03-15
KR100948757B1 (ko) 2010-03-23
KR100935277B1 (ko) 2010-01-06
EP1196172A2 (en) 2002-04-17
ATE304358T1 (de) 2005-09-15
DE60020613T2 (de) 2006-03-16
HK1076723A1 (en) 2006-01-27
US20060135521A1 (en) 2006-06-22
US20020061910A1 (en) 2002-05-23
US20060142289A1 (en) 2006-06-29
ATE305307T1 (de) 2005-10-15
DE60023043D1 (de) 2006-02-16
ATE320257T1 (de) 2006-04-15
CO5190662A1 (es) 2002-08-29
DE60022917D1 (de) 2006-02-09
NZ515885A (en) 2004-08-27
WO2001001973A2 (en) 2001-01-11
EP2090312A1 (en) 2009-08-19
WO2001001973A3 (en) 2002-01-17
DE60022916T2 (de) 2006-07-06
PT1459751E (pt) 2005-11-30
DE60035232T2 (de) 2008-02-14
KR100704319B1 (ko) 2007-04-09
CL2008002866A1 (es) 2009-01-09
TWI294779B (en) 2008-03-21
ES2285645T3 (es) 2007-11-16
US20060135520A1 (en) 2006-06-22
HUP0201623A2 (en) 2002-09-28
PE20010684A1 (es) 2001-06-24
US20080103145A1 (en) 2008-05-01
EA200700232A1 (ru) 2007-06-29
IL187512A0 (en) 2008-06-05
US7338953B2 (en) 2008-03-04
TW200920378A (en) 2009-05-16
DE60035232D1 (de) 2007-07-26
CN1660111A (zh) 2005-08-31
WO2001001973A8 (en) 2001-05-17
US6987107B2 (en) 2006-01-17
EP1196172B1 (en) 2006-03-15
DE60026704D1 (de) 2006-05-11
EA011094B1 (ru) 2008-12-30
EA200801806A1 (ru) 2008-12-30
TW200607509A (en) 2006-03-01
TW200607512A (en) 2006-03-01
TW200914027A (en) 2009-04-01
CA2643231A1 (en) 2001-01-11
NO20091168L (no) 2002-02-19
BR0012136A (pt) 2002-06-11
DE60026627D1 (de) 2006-05-04
DK1196172T3 (da) 2006-06-19
GEP20094798B (en) 2009-10-26
SK19382001A3 (sk) 2002-07-02
US7241762B2 (en) 2007-07-10
CN1289090C (zh) 2006-12-13
MXPA02000562A (es) 2002-07-02
SK286667B6 (sk) 2009-03-05
DE60022916D1 (de) 2006-02-09
JP2006321815A (ja) 2006-11-30
CA2375908A1 (en) 2001-01-11
DE60022692T2 (de) 2006-06-22
DE60019473D1 (de) 2005-05-19
PL196996B1 (pl) 2008-02-29
DE60022692D1 (de) 2005-10-20
KR20050053799A (ko) 2005-06-08
TW200407146A (en) 2004-05-16
DE60026704T2 (de) 2006-10-19
ATE296634T1 (de) 2005-06-15
DK1632234T3 (da) 2007-09-17
TW200607510A (en) 2006-03-01
DE60022917T2 (de) 2006-06-29
SK286668B6 (sk) 2009-03-05
HK1049630A1 (en) 2003-05-23
ES2258010T3 (es) 2006-08-16
US20040147614A1 (en) 2004-07-29
TWI298254B (en) 2008-07-01
US6465458B1 (en) 2002-10-15
ES2247572T3 (es) 2006-03-01
CZ20014625A3 (cs) 2002-08-14
TWI293250B (en) 2008-02-11
JP2006143749A (ja) 2006-06-08
ES2258251T3 (es) 2006-08-16
PL352252A1 (en) 2003-08-11
HUP0201623A3 (en) 2004-12-28
US6642235B2 (en) 2003-11-04
IL187513A0 (en) 2008-06-05
US20030040464A1 (en) 2003-02-27
NZ533243A (en) 2005-12-23
US20090247528A1 (en) 2009-10-01
DE60026627T2 (de) 2007-02-01
SK286864B6 (sk) 2009-06-05
SK286104B6 (sk) 2008-03-05
KR20020015363A (ko) 2002-02-27
PT1459750E (pt) 2005-08-31
KR20090087135A (ko) 2009-08-14
ATE364386T1 (de) 2007-07-15
AU2004202096A1 (en) 2004-06-10
US6610690B2 (en) 2003-08-26
MY137348A (en) 2009-01-30
US20020128173A1 (en) 2002-09-12
US7723334B2 (en) 2010-05-25
ES2246488T3 (es) 2006-02-16
AU771258B2 (en) 2004-03-18
KR100717660B1 (ko) 2007-05-15
ES2246487T3 (es) 2006-02-16
US20020086864A1 (en) 2002-07-04
US20040058925A1 (en) 2004-03-25
NO20016406D0 (no) 2001-12-28
TWI245631B (en) 2005-12-21
US6703389B2 (en) 2004-03-09
US20080103147A1 (en) 2008-05-01
US7276503B2 (en) 2007-10-02
DK1459750T3 (da) 2005-08-15
EA200801805A1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
CL2008002868A1 (es) Uso de reboxetina racemica o una sal de la misma para el tratamiento o prevencion de la fibromialgia u otro desorden somatoforme, neuropatia periferica, migraña, dolor de cabeza y sindrome de fatiga cronica.
ATE286393T1 (de) Formulation von 5-ht agonisten
TR200000756T2 (tr) Davranış bozukluğu tedavisi.
NO20072839L (no) 4-hydroksybenzomorfaner
PT1202724E (pt) Metodo para tratamento da dor cronica utilizando inibidores mek
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
PT1143967E (pt) Utilizacao de derivados anticonvulsivos para o tratamento de cefaleias em salvas
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
EP1435945A4 (en) TRANSDERMAL ANTIMIGRAINE THERAPY
PT885098E (pt) Agente de proteccao da madeira para trabalhos de manutencao
BR0015436A (pt) Sais de hidroxieicosatetraenoato, composições e métodos de uso no tratamento de distúrbios dos olhos secos
PT1089704E (pt) Locao tricologica para aplicacao topica
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
ES2167401T3 (es) Uso de ascorbil-gamma-linolenato o un ascorbil-dihomo-gamma-linolenato para el tratamiento de asma, cancer, enfermedades cardiovasculares y anti-inflamatorias.
DE60019162D1 (de) Zolmitriptanhaltige arzneizusammensetzungen
BR0017157A (pt) Derivados de 6-hidroxi-indazol para o tratamento de glaucoma
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
UY27401A1 (es) Método para el tratamiento del insomnio primario
ES2194104T3 (es) Uso de selegilina para el tratamiento de la perdida de audicion en mamiferos.
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
ATE219665T1 (de) Dosisformen und deren verwendungen
ATE218881T1 (de) Pharmazeutische zusammensetzung mit mutiertem tyrosin 353 ezrin